← All trials
NCT01375920
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2011
- Primary completion
- Feb 1, 2013
- Completion date
- Jun 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 190
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Northumberland, Tyne and Wear NHS Foundation TrustLead sponsor
- Newcastle UniversityOverall official - principal investigator
- Northumberland, Tyne and Wear NHS Foundation TrustOverall official - principal investigator
- University of LeedsOverall official - principal investigator
- University of ManchesterOverall official - principal investigator
- Newcastle UniversityStudy director
- Newcastle UniversityStudy chair
- Northumberland, Tyne and Wear NHS Foundation TrustSponsor investigator
- National Institute for Health Research, United KingdomCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.